Literature DB >> 11491166

Nasal potential difference measurements in patients with atypical cystic fibrosis.

M Wilschanski1, H Famini, N Strauss-Liviatan, J Rivlin, H Blau, H Bibi, L Bentur, Y Yahav, H Springer, M R Kramer, A Klar, A Ilani, B Kerem, E Kerem.   

Abstract

The diagnosis of cystic fibrosis (CF) is based on characteristic clinical and laboratory findings. However, a subgroup of patients present with an atypical phenotype that comprises partial CF phenotype, borderline sweat tests and one or even no common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. The aim of this study was to evaluate the role of nasal potential difference (PD) measurements in the diagnosis of CF patients with an atypical presentation and in a population of patients suspected to have CF. Nasal PD was measured in 162 patients from four different groups: patients with classical CF (n = 31), atypical phenotype (n = 11), controls (n = 50), and patients with questionable CF (n = 70). The parameter, or combination of nasal PD parameters was calculated in order to best discriminate all CF patients (including atypical CF) from the non-CF group. The patients with atypical CF disease had intermediate values of PD measurements between the CF and non-CF groups. The best discriminate model that assigned all atypical CF patients as CF used: e(response to chloride-free and isoproterenol/response to amiloride) with a cut-off >0.70 to predict a CF diagnosis. When this model was applied to the group of 70 patients with questionable CF, 24 patients had abnormal PD similar to the atypical CF group. These patients had higher levels of sweat chloride concentration and increased rate of CFTR mutations. Nasal potential difference is useful in diagnosis of patients with atypical cystic fibrosis. Taking into account both the sodium and chloride transport elements of the potential difference allows for better differentiation between atypical cystic fibrosis and noncystic fibrosis patients. This calculation may assist in the diagnostic work-up of patients whose diagnosis is questionable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11491166     DOI: 10.1183/09031936.01.00092501

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

Review 1.  Patterns of GI disease in adulthood associated with mutations in the CFTR gene.

Authors:  Michael Wilschanski; Peter R Durie
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

Review 2.  Cystic fibrosis: terminology and diagnostic algorithms.

Authors:  K De Boeck; M Wilschanski; C Castellani; C Taylor; H Cuppens; J Dodge; M Sinaasappel
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

3.  Nasal potential difference measurements to assess CFTR ion channel activity.

Authors:  Steven M Rowe; John Paul Clancy; Michael Wilschanski
Journal:  Methods Mol Biol       Date:  2011

4.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.

Authors:  Liat Linde; Stephanie Boelz; Malka Nissim-Rafinia; Yifat S Oren; Michael Wilschanski; Yasmin Yaacov; Dov Virgilis; Gabriele Neu-Yilik; Andreas E Kulozik; Eitan Kerem; Batsheva Kerem
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

5.  Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis.

Authors:  Joshua D Groman; Barbara Karczeski; Molly Sheridan; Terry E Robinson; M Daniele Fallin; Garry R Cutting
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

6.  [Atypical cystic fibrosis. First diagnosed by chronic rhinosinusitis].

Authors:  J G Mainz; S Dornaus; C Dopfer; J F Beck; A Müller
Journal:  HNO       Date:  2009-08       Impact factor: 1.284

Review 7.  Atypical cystic fibrosis: identification in the primary care setting.

Authors:  Carrie A Schram
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

8.  Urogenital abnormalities in male children with cystic fibrosis.

Authors:  H Blau; E Freud; H Mussaffi; M Werner; O Konen; V Rathaus
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

Review 9.  Patterns of gastrointestinal disease associated with mutations of CFTR.

Authors:  Michael Wilschanski
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 10.  Toward inclusive therapy with CFTR modulators: Progress and challenges.

Authors:  Jennifer Guimbellot; Jyoti Sharma; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2017-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.